|
GB0500492D0
(en)
|
2005-01-11 |
2005-02-16 |
Cyclacel Ltd |
Compound
|
|
US20060281768A1
(en)
|
2005-06-10 |
2006-12-14 |
Gaul Michael D |
Thienopyrimidine and thienopyridine kinase modulators
|
|
AU2007325280B2
(en)
|
2006-11-28 |
2011-03-10 |
Dana-Farber Cancer Institute, Inc. |
Combination of IAP inhibitors and FLT3 inhibitors
|
|
EP2133095A4
(en)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
PHARMACEUTICAL COMPOSITION
|
|
JP2011500808A
(ja)
|
2007-10-24 |
2011-01-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
複素環アミドｔ型カルシウムチャネルアンタゴニスト
|
|
FR2926553B1
(fr)
|
2008-01-23 |
2010-02-19 |
Sanofi Aventis |
Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
|
|
US20110183975A1
(en)
|
2008-10-07 |
2011-07-28 |
Yasuhiro Goto |
Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
|
|
CN101723936B
(zh)
|
2008-10-27 |
2014-01-15 |
上海睿星基因技术有限公司 |
激酶抑制剂及其在药学中的用途
|
|
UY32203A
(es)
|
2008-10-29 |
2010-05-31 |
Astrazeneca Ab |
Amino pirimidinas y su uso en terapia
|
|
CA2755976C
(en)
|
2009-03-23 |
2020-04-07 |
Ambit Biosciences Corporation |
Methods of treatment using combination therapy
|
|
CN102471339A
(zh)
|
2009-07-15 |
2012-05-23 |
雅培制药有限公司 |
激酶的吡咯并吡啶抑制剂
|
|
MX342164B
(es)
|
2010-06-23 |
2016-09-19 |
Hanmi Science Co Ltd |
Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
EP4119551A1
(en)
|
2011-07-27 |
2023-01-18 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino)pyrimidine compounds
|
|
WO2013146963A1
(ja)
|
2012-03-28 |
2013-10-03 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2014155300A2
(en)
|
2013-03-28 |
2014-10-02 |
Aurigene Discovery Technologies Limited |
Substitued pyrimidine amine derivatives as tak-1 inhibitors
|
|
CN110229142A
(zh)
|
2014-04-04 |
2019-09-13 |
希洛斯医药品股份有限公司 |
细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
|
|
EP3778584A1
(en)
|
2014-06-19 |
2021-02-17 |
ARIAD Pharmaceuticals, Inc. |
Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
|
|
CN106458969A
(zh)
|
2014-08-25 |
2017-02-22 |
四川海思科制药有限公司 |
一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
|
|
CN105085489B
(zh)
|
2014-11-05 |
2019-03-01 |
益方生物科技（上海）有限公司 |
嘧啶或吡啶类化合物、其制备方法和医药用途
|
|
CA2976752C
(en)
|
2015-02-20 |
2019-12-17 |
Daiichi Sankyo Company, Limited |
Method for treating cancer by combined use
|
|
WO2016155655A1
(zh)
|
2015-04-03 |
2016-10-06 |
上海瑛派药业有限公司 |
Parp抑制剂固体药物剂型及其应用
|
|
KR101799781B1
(ko)
|
2015-07-23 |
2017-11-22 |
재단법인 강릉과학산업진흥원 |
소뼈 추출분말의 제조방법
|
|
US10829484B2
(en)
|
2015-07-28 |
2020-11-10 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
KR102110573B1
(ko)
|
2015-08-13 |
2020-05-13 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
Irak4억제제 및 이의 용도
|
|
AU2016324920B2
(en)
|
2015-09-14 |
2022-03-03 |
Brunangelo Falini |
Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
|
|
US10927418B2
(en)
|
2015-11-11 |
2021-02-23 |
Celator Pharmaceuticals, Inc. |
Assays and methods for selecting a treatment regimen for a subject with leukemia
|
|
CA3017408C
(en)
|
2016-03-15 |
2025-08-19 |
Oryzon Genomics, S.A. |
LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
|
|
CA3018155A1
(en)
*
|
2016-03-29 |
2017-10-05 |
Astellas Pharma Inc. |
Combination therapy for the treatment of acute myeloid leukemia
|
|
ES2805976T3
(es)
|
2016-06-30 |
2021-02-16 |
Janssen Pharmaceutica Nv |
Derivados heteroaromáticos en calidad de inhibidores de NIK
|
|
WO2018092020A1
(en)
|
2016-11-15 |
2018-05-24 |
Novartis Ag |
Dose and regimen for hdm2-p53 interaction inhibitors
|
|
US20200039998A1
(en)
|
2016-12-19 |
2020-02-06 |
Epizyme, Inc. |
Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
|
|
ES2938648T3
(es)
|
2017-01-17 |
2023-04-13 |
Astrazeneca Ab |
Inhibidores selectivos de JAK1
|
|
KR102175710B1
(ko)
|
2017-01-23 |
2020-11-06 |
주식회사 엘지화학 |
폴리아릴렌 설파이드 수지 조성물
|
|
EP3789386A1
(en)
|
2017-01-26 |
2021-03-10 |
Hanmi Pharm. Co., Ltd. |
Pyrimidine compound and pharmaceutical use thereof
|
|
TWI821174B
(zh)
|
2017-02-21 |
2023-11-11 |
加拿大商艾普托斯生物科學公司 |
治療血液惡性腫瘤患者的方法
|
|
EP3661511A1
(en)
|
2017-08-01 |
2020-06-10 |
Julius-Maximilians-Universität Würzburg |
Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
|
|
AU2018354423B2
(en)
|
2017-10-27 |
2024-11-07 |
Plexxikon Inc. |
Formulations of a compound modulating kinases
|
|
EP3755703B1
(en)
|
2018-02-20 |
2022-05-04 |
Incyte Corporation |
N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
|
|
SG11202012425QA
(en)
|
2018-07-13 |
2021-01-28 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
KR101954370B1
(ko)
|
2018-07-25 |
2019-03-05 |
한미약품 주식회사 |
피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
|
|
KR102297587B1
(ko)
|
2018-08-07 |
2021-09-06 |
재단법인 대구경북첨단의료산업진흥재단 |
치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN113166110B
(zh)
|
2018-12-12 |
2023-08-11 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
WO2020171649A1
(ko)
|
2019-02-22 |
2020-08-27 |
한미약품 주식회사 |
Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
|
|
BR112021016522A2
(pt)
|
2019-02-22 |
2021-10-26 |
Hanmi Pharm. Co., Ltd. |
Composição farmacêutica para o tratamento da leucemia mieloide aguda
|
|
KR20200102948A
(ko)
|
2019-02-22 |
2020-09-01 |
한미약품 주식회사 |
Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
|
|
KR20200102949A
(ko)
|
2019-02-22 |
2020-09-01 |
한미약품 주식회사 |
Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
|
|
EA202290154A1
(ru)
|
2019-06-27 |
2022-03-29 |
Ханми Фарм. Ко., Лтд. |
Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
|
|
KR20210038366A
(ko)
|
2019-09-30 |
2021-04-07 |
한미약품 주식회사 |
Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
|
|
CN115151534B
(zh)
|
2020-02-14 |
2024-02-06 |
南京药石科技股份有限公司 |
白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
|
|
EP4241773A4
(en)
|
2020-11-05 |
2024-10-16 |
Hanmi Pharm. Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA WITH FLT3 INHIBITOR
|
|
KR20230056331A
(ko)
|
2021-10-20 |
2023-04-27 |
한미약품 주식회사 |
급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
|
|
AU2023372170A1
(en)
|
2022-11-04 |
2025-04-24 |
Hanmi Pharm. Co., Ltd. |
Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof
|
|
WO2024124199A1
(en)
|
2022-12-10 |
2024-06-13 |
Aptose Biosciences Inc. |
Methods for treating patients with hematologic malignancies
|
|
CN121586574A
(zh)
|
2023-05-31 |
2026-02-27 |
韩美药品株式会社 |
髓样激酶组抑制剂的固体分散体和包含所述固体分散体的药物组合物
|